Resource data sheet
DNA Bank Top
Please review the QC test results indicated by check icon below as well as clone information before placing your order.

pENTER-EGFR T790M/del19 (#RDB15490)

Gateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations.

Clone info. Gateway(R) entry vector of human epidermal growth factor receptor (EGFR) mutant, T790M and deletion in exon 19, EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations.
Comment cDNA was obtained from HCC-827 cells. Expression was confirmed by the depositor with western blotting after cloned into pLenti6.3 vector (by LR clonase II reaction). This clone contains a cDNA fragment corresponding to the 258nt to 3890nt of NM_005228.4. Known differences (at least) : 15nt (del19) deletion at 2493 to 2507nt ; C to T substitution at 2626nt (T790M).
Vector backbone pENTR (plasmid)
Size of vector backbone 2.6 kb
Selectable markers Kan^r
Gene/insert name human EGFR cDNA
Depositor|Developer Katayama, Ryohei |
 

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
Please visit Information of Request for Distribution.[link] 
Terms and conditions for distribution In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR is requested. (Uchibori, K et al. Nat. Commun. 8: 14768, 2017)
Remarks
Gateway® Entry clone. Please refer Life Technologies Corporation signs license agreement with RIKEN BRC.
提供案内 (日本国内) [open/close]

必要書類
提供依頼書  [依頼書の記入例 ]
提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ]
手続きの概要は、「提供申込みについて[link]」をご覧ください。
MTAに書く使用条件 利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する(Uchibori, K et al. Nat. Commun. 8: 14768, 2017)。
備考
Gateway®テクノロジーを用いたエントリークローンです。「Gateway®テクノロジーを用いたクローンの提供と寄託のご案内」をご覧ください。

Catalog # Resource name Shipping form Fee (non-profit org.)
RDB15490 pENTER-EGFR T790M/del19 DNA solution

Please review the QC test results indicated by check icon below as well as clone information before placing your order.

How to cite this biological resource

Materials & Methods section:

The pENTER-EGFR T790M/del19 was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB15490).

Reference section:

Uchibori, K., Inase, N., Araki, M., Kamada, M., Sato, S., Okuno, Y., Fujita, N., Katayama, R., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. [link to RRC of NBRP]

Further references such as user reports and related articles (go to bottom)

QC test results

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet RDB15490_A7K8p1-2.pdf check

Nucleotide sequence of a portion of this resource (if available).

Primer: rrnBT1ter_F2 (Pr0531)
Region: rrnB T1 ter,attL1,insert 5'
Sequence file: RDB15490_A7K8d.seq check
>D04925A3_A7K8_1_rrnBT1ter_F2_C04_07_ABI24.ab1
    1 NNNNNNNNNN NNNNNNNNNN CCTTTCGTTT NNTTTGATGC CTGGCAGTTC CCTACTCTCG
   61 CGTTAACGCT AGCATGGATG TTTTCCCAGT CACGACGTTG TAAAACGACG GCCAGTCTTA
  121 AGCTCGGGCC CCAAATAATG ATTTTATTTT GACTGATAGT GACCTGTTCG TTGCAACAAA
  181 TTGATGAGCA ATGCTTTTTT ATAATGCCAA CTTTGTACAA AAAAGCAGGC TCCGCGGCCG
  241 CCCCCTTCAC CATGCGACCC TCCGGGACGG CCGGGGCAGC GCTCCTGGCG CTGCTGGCTG
  301 CGCTCTGCCC GGCGAGTCGG GCTCTGGAGG AAAAGAAAGT TTGCCAAGGC ACGAGTAACA
  361 AGCTCACGCA GTTGGGCACT TTTGAAGATC ATTTTCTCAG CCTCCAGAGG ATGTTCAATA
  421 ACTGTGAGGT GGTCCTTGGG AATTTGGAAA TTACCTATGT GCAGAGGAAT TATGATCTTT
  481 CCTTCTTAAA GACCATCCAG GAGGTGGCTG GTTATGTCCT CATTGCCCTC AACACAGTGG
  541 AGCGAATTCC TTTGGAAAAC CTGCAGATCA TCAGAGGAAA TATGTACTAC GAAAATTCCT
  601 ATGCCTTAGC AGTCTTATCT AACTATGATG CAAATAAAAC CGGACTGAAG GAGCTGCCCA
  661 TGAGAAANTT ACAGGAAATC CTGCATGGCG CCGTGCGGTT CAGCAACAAC CCTGCCCTGT
  721 GCAATGTGGA GAGCATCCAG TGGCGGGACA TAGTCAGCAG TGACTTTCTC AGCAACATGT
  781 CGATGGACTT CCAGAACCAC CTGGGCAGCT GCCAAAAGTG TGNTCCAAGC TGTCCCAATN
  841 NNANCTGCTG GGGTGCANGA NANGANAANT GCCAGAAACT GANCAAAATC ATCTGNGCCC
  901 AGCAGNGCNC CGGGCGCTGC CNNGGCAAGN CCCCCNANNN NNNGCTGCCA CAACCANNNN
961 NNTGNNNNNN NNCNNNNCCC CNGGNNNNNC NNNNNNNNNN
//
Primer: pDONR_R (Pr0071)
Region: attL2,insert 3'
Sequence file: RDB15490_A7K8e.seq check
>D04925A3_A7K8_1_pDONR_R_C08_08_ABI24.ab1
    1 NNNNNNNNNN NNNNNNNNCN NTGNNNNTGT AATACGACTC ACTATAGGGG ANATCAGCTG
   61 GATGGCAAAT AATGATTTTA TTTTGACTGA TAGTGACCTG TTCGTTGCAA CAAATTGATA
  121 AGCAATGCTT TCTTATAATG CCAACTTTGT ACAAGAAAGC TGGGTCGGCG CGCCCACCCT
  181 TTCATGCTCC AATAAATTCA CTGCTTTGTG GCGCGACCCT TAGGTATTCT GCATTTTCAG
  241 CTGTGGAGCC CTTAAAGATG CCATTTGGCT TGGCTTCCTT GGGAAAGAAG TCCTGCTGGT
  301 AGTCAGGGTT GTCCAGGCTA ATTTGGTGGC TGCCTTTCTG GGCCCAGTGG GCAGGGCTGT
  361 CGAATGTGCT GTTGACACAG GTGGGCTGGA CAGTGTTGAG ATACTCGGGG TTGCCCACTG
  421 CAGTGCTGTG GGGGTCCTGG TAGTGTGGGT CTCTGCTGGG CGCGGGGTTC AGAGGCTGAT
  481 TGTGATAGAC AGGATTCTGC ACAGAGCCAG CGGGCCTTTT GGGAACGGAC TGGTTTATGT
  541 ATTCAGGCAC TGGGAGGAAG GTGTCGTCTA TGCTGTCCTC AGTCAAGGCG CCTGTGGGGT
  601 CTGANCTGTA TCGCTGCAAG AAGCTGTCTT CCTTGATGGG ACAGCTTTGC AGCCCATTTC
  661 TATCNATGCA AGCCACGGNG GAATTGTTGC TGGTTGCACT CAGANANCTC NNNANGGGAN
  721 TCCGTGANGN GGANGGGCTG CTGNANAANC CCTGCTGTGG GNNGANGNAN TCGNCNGCNT
  781 CCNCCNCNNC NTNCNTGNCN NCNNNNTNCN TCNNGNNNNN GNANANNNNN GNANNCNGNN
841 NNANTNNNNN AANGCNTNNN TNNNNNCNNN NNNNNNN
//
Primer: EGFR-F5 (Pr0313)
Region: insert mid(T790M/del19)
Sequence file: RDB15490_A7K8f.seq check
>D04925A3_A7K8_1_EGFR-F5_C09_09_ABI24.ab1
    1 NNNNNNNNNN NNNNNNNNNN NNNNNGGNNG GTGGGGGCCC TCCTCTTGCT GCTGGTGGTG
   61 GCCCTGGGGN NCGGCCTCTT CNTGCGAAGG CGCCACATCG TTCGGAAGCG CACGCTGCGG
  121 AGGCTGCTGC AGGAGAGGGA GCTTGTGGAG CCTCTTACAC CCAGTGGAGA AGCTCCCAAC
  181 CAAGCTCTCT TGAGGATCTT GAAGGAAACT GAATTCAAAA AGATCAAAGT GCTGGGCTCC
  241 GGTGCGTTCG GCACGGTGTA TAAGGGACTC TGGATCCCAG AAGGTGAGAA AGTTAAAATT
  301 CCCGTCGCTA TCAAGACATC TCCGAAAGCC AACAAGGAAA TCCTCGATGA AGCCTACGTG
  361 ATGGCCAGCG TGGACAACCC CCACGTGTGC CGCCTGCTGG GCATCTGCCT CACCTCCACC
  421 GTGCAGCTCA TCATGCAGCT CATGCCCTTC GGCTGCCTCC TGGACTATGT CCGGGAACAC
  481 AAAGACAATA TTGGCTCCCA GTACCTGCTC AACTGGTGTG TGCAGATCGC AAAGGGCATG
  541 AACTACTTGG AGGACCGTCG CTTGGTGCAC CGCGACCTGG CAGCCAGGAA CGTACTGGTG
  601 AAAACACCGC AGCATGTCAA GATCACAGAT TTTGGGCTGG CCAAACTGCT GGGTGCGGAA
  661 GAGAAAGAAT ACCATGCAGA AGGAGGCAAA GTGCCTATCA AGTGGATGGC ATTGGAATCA
  721 ATTTTACACA GAATCTATAC CCACCAGAGT GATGTCTGGA GCTACGGNNT GANCGTTTGG
  781 GAGTTGATGA NCTTTGGATC CAAGCCATAT GACGGAATCC CTGCCNGCGA GATCTCCTCC
  841 NTCCTNGANA AAGGANAACG CCNCCNTCAG CCNCCCATAT GTANCNTCGA NGNCTACATG
  901 ATCATGGNCN ANNGCTGGNT GATAGNNGCN NANAGNCGCC NNAANTTNCN NNNNNNGATC
961 ATCNNNNNNN NNN
//

Please visit Sequencing and PCR primers for primer information.

References

Original, user report and related articles

original Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. [link to RRC of NBRP]